By staff writers

October 4, 2019 -- The U.S. Food and Drug Administration (FDA) should continue to assess the effects of new guidance for controlling the risk of bacterial contamination of platelets in blood collection establishments and transfusion services, according to America's Blood Centers (ABC), a large network of community-based, independent blood programs in North America.

A final guidance document on blood products was issued in September. It offers recommendations for controlling risk for stored platelets intended for transfusion, including testing methods with culture-based or rapid detection devices for bacterial contamination and ensuring that procedures are in place to track the testing status of platelet products.

While the final guidance allows for an extended implementation period, significant operational complexities remain that could affect patient access to platelets, especially in rural and underserved communities, the organization said in a statement.

There is no FDA-approved system available for the large-volume delayed sampling (LVDS) option for seven-day dating included in the guidance, ABC noted. The FDA should expeditiously approve a technology to give blood centers enough time to consider this option and time for the ramp-up required by manufacturers to meet potential market needs, ABC said.

FDA approves Roche's cobas babesiosis test for blood donations
Roche's cobas Babesia test for screening whole blood specimens from blood donors is now approved by the U.S. Food and Drug Administration (FDA).
Fisher set to market Verax platelet contamination test
Verax Biomedical has enlisted Fisher Healthcare, the lab product distributor subsidiary of Thermo Fisher Scientific, as an exclusive distributor in the...

Copyright © 2019

Last Updated np 10/3/2019 4:08:39 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.